Physician profile

John D Blevins

Neurology (Psychiatry & Neurology) · West Columbia, SC

NPI 1467423608

$1,640.02

in general payments reported to CMS, 2019-2025

27 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $302.34 2021-2022
Amgen INC. $232.60 2019-2021
Novartis Pharmaceuticals Corporation $137.24 2019-2021
Supernus Pharmaceuticals, INC. $134.98 2019-2021
Sunovion Pharmaceuticals INC. $130.60 2019
Ge Healthcare $119.60 2019
Insulet Corporation $69.19 2019
Acadia Pharmaceuticals INC $62.58 2019-2020
Allergan, INC. $50.66 2020
Mallinckrodt Enterprises LLC $49.55 2019
Upsher-Smith Laboratories LLC $36.39 2019
Boston Scientific Corporation $31.44 2019
Amneal Pharmaceuticals LLC $28.40 2020-2021
Teva Pharmaceuticals USA, INC. $25.91 2021
Genzyme Corporation $24.83 2019
Show all 27 companies
CompanyGeneral paymentsYearsTop products
Mannkind Corporation $22.63 2019
Bausch Health US, LLC $22.23 2019
Biotronik INC. $20.05 2021
Alexion Pharmaceuticals, INC. $19.70 2019
Avanir Pharmaceuticals, INC. $19.07 2019
Greenwich Biosciences, INC. $17.73 2019
Lilly USA, LLC $15.89 2019
Shire North American Group INC $14.58 2019
Pfizer INC. $14.04 2021
Genentech USA, INC. $13.88 2019
Novo Nordisk INC $12.71 2020
Grifols USA, LLC $11.20 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John D Blevins

$1,640.02

in general payments reported 2019-2025

Years
2019-2022
Top company
Abbvie INC.

https://glasscript.com/doctor/20578/john-d-blevins

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.